Nicotine Science and Policy

Sweden and the UK offer a useful comparison in what happens when smokers have access to credible alternatives. Oral nicotine products and other smoke-free options can change the trajectory of smoking rates when they are available, acceptable and regulated rather than pushed aside. The lesson is not that one product solves everything, but that people need more than warnings and willpower to leave cigarettes behind. Tobacco policy should study where smoking is falling fastest — and ask what made that possible.

The movement away from smoking is already happening in the data. A study showing exclusive vaping rising by 18.8% a year among US adults suggests that many people are not simply adding nicotine products, but replacing cigarettes with smoke-free alternatives. That distinction matters: full switching is where harm reduction has the greatest potential. Policy should pay attention to these behavioural shifts instead of treating all nicotine use as a failure.

When legal review moves slowly, the market does not wait politely. Delays in the FDA process can leave a void that illicit and unapproved products are quick to fill, while responsible pathways remain blocked or uncertain. That is not only a regulatory problem; it is a consumer protection problem. If safer nicotine products are to replace cigarettes, the legal system must be faster, clearer and capable of keeping people inside accountable markets.

Smoking is a major but often neglected driver of poor health among people with schizophrenia spectrum disorders. A 2026 scoping review found preliminary evidence that e-cigarette interventions may be feasible and acceptable in this group, with signs of smoking reduction, short-term abstinence and reduced exposure to tobacco-related carcinogens. The evidence is still limited, with only a small number of studies and important questions about long-term support and generalisability. But for a population where conventional cessation often performs poorly, harm reduction deserves serious clinical attention.

Regulatory meetings should be judged by whether they bring public health closer to real-world solutions. Responses to the FDA’s tobacco regulatory agenda show how wide the gap remains between precaution, evidence and the needs of adults who smoke. If the process treats lower-risk nicotine products mainly as a threat, it risks missing their potential role in reducing exposure to combustible tobacco. Better regulation starts with listening to evidence, consumers and unintended consequences — not only institutional caution.